Rhythm Biosciences Ltd has released a press release.
Board Renewal / Composition Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Platform Expansion - Gastric Cancer Diagnostic Test Update
- Product and Market Update - Phase 2 Milestone
- Jun 24 Quarterly Activities Report and Appendix 4C
- Mar24 Quarterly Activities Report and Appendix 4C
- Dr David Atkins appointed Chief Executive Officer of Rhythm
Later from Rhythm Biosciences
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
- Receipt of Research & Development Tax Incentive
- Strong Demand in Share Placement to Raise $3.5 million
- Market Update - All End of CY24 Milestones Attained
- Pause in Trading
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences